| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2bb3a52fede77711d08747cbe80c826 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 |
| filingDate |
2006-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e785fb99f5685245cc2f659b247d037d |
| publicationDate |
2008-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008031932-A1 |
| titleOfInvention |
Transdermal atomoxetine formulations and associated methods |
| abstract |
Methods and formulations for delivering atomoxetine compounds that minimize drug metabolism and thus increase the effectiveness of the drug are disclosed. The method may include maximizing the in vivo potency of an atomoxetine compound in a subject by transdermally administering the atomoxetine compound to the subject. The in vivo potency of the atomoxetine compound may be maximized by minimizing the in vivo conversion of the atomoxetine compound to an atomoxetine compound metabolite. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9663455-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11524935-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012245226-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9326935-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8895609-B2 |
| priorityDate |
2006-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |